Willow Biosciences Q1 FY23 Revenue Grows To $203K, Still In Development Stage And On 'A Solid Trajectory'
Willow Biosciences Q1 FY23 Revenue Grows To $203K, Still In Development Stage And On 'A Solid Trajectory'
Willow Biosciences Inc. (OTCQB:CANSF) (TSX:WLLW) released its financial and operating results for the three months ended March 31, 2023, revealing revenue of CA$274,000Â ($203,000) compared to no revenue in Q1 2022. The company is in the development stage and expects to operate at a loss and use cash in operating activities as it conducts research and development on its biosynthesis pathways.
柳樹生物科學公司。(OTCQB：CANSF)(多倫多證券交易所股票代碼：WLLW)發佈了截至2023年3月31日的三個月的財務和運營業績，披露收入27.4萬加元̂(203,000美元)，而2022年第一季度沒有收入。該公司正處於發展階段預計在進行生物合成途徑的研究和開發時，將在運營活動中虧損運營並使用現金。
"The first quarter of this year marked significant progress against our stated goals to foster diversified commercial growth within our portfolio, and create opportunities for near-term revenue generation for the business all while experiencing reduced cash burn", stated Chris Savile, Willow's president and CEO. "We are on a solid trajectory in successfully executing on projects underway while pursuing new agreements, and our legacy yeast strain engineering capabilities along with the complementary BioOxi bio-oxidation platform technology we recently launched further opens up the playing field where we can leverage our technology in pursuit of growth."
今年第一季度標誌著我們宣佈的目標取得了重大進展，即在我們的投資組合中促進多元化的商業增長，並在減少現金消耗的同時為業務創造短期收入的機會。克裡斯·薩維爾，Willow的總裁兼首席執行官。我們正走在成功執行正在進行的專案的堅實軌道上，同時尋求新的協定，我們傳統的酵母菌株工程能力以及我們最近推出的互補的BioOxi生物氧化平臺技術進一步打開了我們可以利用我們的技術追求增長的競爭環境。“
Highlights for the Quarter
本季度的亮點
-
On January 17, 2023, Willow announced a follow-on engagement with Sandhill One, LLC for the next phase in optimizing a proprietary enzyme vital to the development of a large volume active pharmaceutical ingredient used in nutraceutical and pharmaceutical products.
-
On February 22, 2023, Willow announced the appointment of Jim Lalonde, Ph.D. as its newest independent member of the company's board of directors, effective February 21, 2023.
-
On March 22, 2023, Willow and SUANFARMA jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the Willow-owned ingredient, Cannabigerol (CBG). The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
-
On March 28, 2023, Willow announced that the board of directors appointed Dr. Chris Savile, Willow's COO, as president and CEO and Trevor Peters, a director and founder of the company, as chairman, effective March 28, 2023, in connection with Dr. Peter Seufer-Wasserthal's retirement as president and CEO. Dr. Seufer-Wasserthal will continue to be a Director of the company.
-
Willow also announced the appointment of experienced financial executive, Raffi Asadorian, as an independent director to the company's board of directors.
-
Willow ended the quarter with approximately CA$10.5 million of cash as of March 31, 2023, with the company's approved annual budget expected to be fully funded for 2023.
-
Net loss was CA$4.7 million compared to net loss of CA$3 million in Q1 2022.
-
2023年1月17日，Willow宣佈與沙丘一號有限責任公司在優化專利酵素的下一階段，該酵素對開發用於保健食品和醫藥產品的大容量活性藥物成分至關重要。
-
2023年2月22日，威洛宣佈任命吉姆·拉隆德，博士。作為公司董事會的最新獨立成員，自2023年2月21日起生效。
-
2023年3月22日，柳樹和桑法爾瑪共同宣佈，他們已經與SUANFARMA的CIPAN製造基地一起，完成開發以及柳樹自有成分的中試生產工藝，大麻酚(CBG)。即將到來的資格認證和註冊所需的36立方米擴大生產批次將於2023年完成。
-
2023年3月28日，威洛宣佈董事會任命克裡斯·薩維爾博士，柳樹的首席運營官，作為總裁和首席執行官特雷弗·彼得斯、董事人士兼公司創始人擔任董事長，自2023年3月28日起生效，與Peter Seufer-Wasserthal博士的從總裁和首席執行官的位置上退休。休弗-沃瑟爾博士將繼續擔任該公司董事的一員。
-
威洛還宣佈任命一名經驗豐富的財務主管，拉菲·阿薩多裡安，作為獨立的董事進入公司董事會。
-
截至2023年3月31日，Willow在本季度結束時擁有約1050萬加元的現金，該公司批准的2023年年度預算預計將得到全額資金。
-
淨虧損為470萬加元，而2022年第一季度淨虧損為300萬加元。
Photo by Louis Reed on Unsplash
路易·裡德在Unspash上拍攝的照片
Related News
相關新聞
Willow Biosciences Touts Strong Q3 Results, Continues Its Focus On Biosynthetically Produced Cannabinoids
Willow Biosciences吹捧強勁的第三季度業績，繼續專注於生物合成產生的大麻類化合物
Willow Biosciences Announces Q2 2021 Results, Agrees To Supply Cellular Goods With CBG
Willow Biosciences公佈2021年第二季度業績，同意向蜂窩產品供應CBG
譯文內容由第三人軟體翻譯。